P/E ratio for SCYNEXIS (SCYX)
P/E ratio as of April 2024 (TTM): 1.65
According to SCYNEXIS's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 1.64894. At the end of 2022 the company had a P/E ratio of -1.12.
P/E ratio history for SCYNEXIS from 2014 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -1.12 | -77% |
| 2021 | -4.88 | 231.07% |
| 2020 | -1.47 | 57.93% |
| 2019 | -0.9333 | -45.78% |
| 2018 | -1.72 | -30.99% |
| 2017 | -2.49 | 25.9% |
| 2016 | -1.98 | -13.22% |
| 2015 | -2.28 | -86.83% |
| 2014 | -17.3 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Galmed Pharmaceuticals
GLMD | -0.0585 | -103.55% | 🇮🇱 Israel |
 Catalyst Pharmaceuticals CPRX | 13.5 | 720.92% | 🇺🇸 USA |
 Catalent CTLT | -43.4 | -2,730.30% | 🇺🇸 USA |
 KemPharm KMPH | -5.87 | -455.91% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.